专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2002100900A2 HUMAN RECOMBINANT ANTIBODY AGAINST THE HEPATITIS C (HCV) NON STRUCTURAL NS3 PROTEIN, NUCLEIC ACID AND USES THEREOF 审中-公开
标题翻译：人类重组抗乙型肝炎病毒（HCV）非结构型NS3蛋白，核酸及其用途的抗体
公开(公告)号：WO2002100900A2
公开(公告)日：2002-12-19
申请号：PCT/IT2002/000384
申请日：2002-06-11
申请人： BIOSTRANDS S.R.L. , BURIONI, Roberto , CLEMENTI, Massimo
发明人： BURIONI, Roberto , CLEMENTI, Massimo
IPC分类号： C07K16/00
CPC分类号： C07K16/109 , A61K48/00 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C12N2799/028
摘要： An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof.
摘要翻译：描述了丙型肝炎病毒（HCV）的人抗体抗NS3蛋白，以及能够在体外和体内抑制NS3蛋白的解旋酶活性的合成和重组片段及其用途。

72. 发明申请

WO2002060954A1 MATERIALS AND METHODS FOR TREATMENT OF HEPATITIS C 审中-公开
标题翻译：用于治疗乙型肝炎的材料和方法C
公开(公告)号：WO2002060954A1
公开(公告)日：2002-08-08
申请号：PCT/SE2002/000044
申请日：2002-01-14
申请人： KAROLINSKA INNOVATIONS AB , DRAKENBERG, Katarina , PERSSON, Mats, A., A.
发明人： DRAKENBERG, Katarina , PERSSON, Mats, A., A.
IPC分类号： C07K16/10
CPC分类号： C07K16/109 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/56
摘要： The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Futhermore, the invention relates to a method of treating or preventing HCV infection by administration of a vaccine composition comprising the monoclonal antibodies of te invention.
摘要翻译：本发明涉及用于治疗丙型肝炎的材料和方法。更为详细地，本发明涉及针对HCV E1抗原的人单克隆抗体，涉及包含此类抗体的试剂，以及包含此类抗体的疫苗组合物。此外，本发明涉及通过施用包含本发明的单克隆抗体的疫苗组合物来治疗或预防HCV感染的方法。

73. 发明申请

WO02055560A2 MONOCLONAL ANTIBODIES SPECIFIC FOR THE E2 GLYCOPROTEIN OF HEPATITIS C VIRUS AND THEIR USE IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF HEPATITIS C 审中-公开
标题翻译：丙型肝炎病毒乙型肝炎病毒特异性单克隆抗体及其在诊断，治疗和预防乙型肝炎中的应用
公开(公告)号：WO02055560A2
公开(公告)日：2002-07-18
申请号：PCT/US2001/045221
申请日：2001-11-30
IPC分类号： A61K39/395 , A61P1/16 , A61P31/12 , C07K16/08 , C07K16/10 , C07K16/42 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/576 , G01N33/577 , G01N33/68 , A61K39/42 , G01N33/569
CPC分类号： G01N33/6878 , A61K2039/505 , C07K16/109 , C07K16/4216 , C07K2317/21 , C07K2317/55 , C07K2317/565 , G01N33/5767 , G01N2333/18
摘要： The present invention describes the identification and characterization of five human HC E2-specific monoclonal antibodies isolated form a phage display library and their use in the diagnosis, treatment, and prevention of HCV in mammals, preferably humans.
摘要翻译：本发明描述了从噬菌体展示文库分离的五种人HC E2特异性单克隆抗体的鉴定和鉴定及其在哺乳动物，优选人类中诊断，治疗和预防HCV的用途。

74. 发明申请

WO01058459A1 REMEDIES FOR HEPATITIS C 审中-公开
标题翻译： HEPATITIS C的补救措施
公开(公告)号：WO01058459A1
公开(公告)日：2001-08-16
申请号：PCT/JP2001/000967
申请日：2001-02-13
IPC分类号： A61K31/737 , A61P31/20 , C07K16/10 , C12N5/02 , A61K38/17 , A61K39/395 , A61K45/00 , C12N15/09 , G01N33/50 , G01N33/53 , G01N33/576
CPC分类号： A61K31/737 , A61K2039/505 , C07K16/109 , C07K2317/21 , C07K2317/622
摘要： A substance inhibiting the binding of hepatitis C virus E2/NS1 protein to cells with potential infection with hepatitis C virus, cells with the expression of CD81 or CD81. Thus, novel drugs having antiviral effects (inhibition of the infection with HCV, etc.) can be provided.
摘要翻译：抑制丙型肝炎病毒E2 / NS1蛋白与具有丙型肝炎病毒潜在感染的细胞的结合的物质，具有CD81或CD81表达的细胞。因此，可以提供具有抗病毒作用（抑制HCV感染等）的新型药物。

75. 发明申请

WO00005266A1 ANTI HEPATITIS C VIRUS ANTIBODY AND USES THEREOF 审中-公开
标题翻译：抗乙型肝炎病毒抗体及其用途
公开(公告)号：WO00005266A1
公开(公告)日：2000-02-03
申请号：PCT/EP1999/005173
申请日：1999-07-20
IPC分类号： G01N33/53 , A61K39/29 , A61K39/395 , A61P31/12 , C07K14/18 , C07K16/10 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/10 , C12P21/08 , C12R1/91 , G01N33/569 , G01N33/576 , G01N33/577
CPC分类号： G01N33/5767 , A61K2039/505 , C07K16/109 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.
摘要翻译：描述了特异性识别HCV糖蛋白E2的构象依赖性表位并能够中和E2蛋白与敏感细胞的结合的新型抗体。此外，提供了由上述抗体识别的抗原和表位以及编码所述抗体的多核苷酸。还提供了包含所述多核苷酸的载体以及转化的宿主细胞及其在所述抗体的产生中的用途。此外，提供药物和诊断组合物，其包含任何上述抗体，抗原，表位，多核苷酸，载体或细胞。进一步描述了上述抗体，抗原，多核苷酸和载体在过继性免疫治疗中的用途，优选用于治疗或预防肝移植期间的HCV感染。

76. 发明申请

WO99050301A2 EPITOPES IN VIRAL ENVELOPE PROTEINS AND SPECIFIC ANTIBODIES DIRECTED AGAINST THESE EPITOPES: USE FOR DETECTION OF HCV VIRAL ANTIGEN IN HOST TISSUE 审中-公开
标题翻译：病毒包膜蛋白的抗原决定和针对这些抗原决定簇的特异性抗体：用于检测病毒组织中的HCV病毒抗原
公开(公告)号：WO99050301A2
公开(公告)日：1999-10-07
申请号：PCT/EP1999/002154
申请日：1999-03-29
IPC分类号： G01N33/576 , C07K14/18 , C07K16/10 , C12N5/10 , C12N5/20 , C12N15/02 , C12P21/08 , C12R1/91
CPC分类号： C07K14/005 , C07K16/109 , C12N2770/24222
摘要： Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.
摘要翻译：鉴定出HCV包膜蛋白上两个新表位的抗体，其允许常规检测来自宿主的组织或细胞中的天然HCV包膜抗原。新表位是：E1区aa 307-326和E2 aa 395-415的N末端超变区。令人惊讶的是，我们的特征是抗体与E2的高变区域的各种序列反应。描述针对这些表位并且允许常规检测病毒抗原的特异性单克隆抗体。

77. 发明申请

WO98039360A1 ANTIGENIC STRUCTURAL PEPTIDE, ANTIGENIC AND IMMUNOGENIC COMPOUNDS AND USES FOR DETECTING, PREVENTING AND TREATING AN HCV INFECTION 审中-公开
标题翻译：抗原结构肽，抗原和免疫组织化学物质及用于检测，预防和治疗HCV感染的用途
公开(公告)号：WO98039360A1
公开(公告)日：1998-09-11
申请号：PCT/FR1998/000442
申请日：1998-03-05
IPC分类号： G01N33/576 , A61K38/00 , A61K39/12 , A61P31/12 , C07K14/18 , C07K16/10 , C12Q1/70 , G01N33/569 , A61K38/16
CPC分类号： C07K14/005 , A61K38/00 , C07K16/109 , C12N2770/24222
摘要： The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) of the hepatitis C virus (HCV) or any variant of said virus, excluding any protein or peptide compound comprising or consisting of said N-terminal end. The invention is characterised in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in alpha helix, a second peptide fragment having a secondary structure in alpha helix and a third peptide bond fragment linking the two alpha helixes, these two alpha helixes being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all or part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.
摘要翻译：本发明涉及由针对多肽的抗体鉴定的结构肽，其包含核心的N-末端的2-45个氨基酸序列或丙型肝炎病毒（HCV）的核衣壳（p21）或所述的任何变体病毒，不包括由所述N-末端组成或由所述N-末端组成的任何蛋白质或肽化合物。本发明的特征在于其包含由至少第一个具有α螺旋二级结构的肽片段，α螺旋中具有二级结构的第二肽片段和连接两个α螺旋的第三肽键片段组成的三级结构，这两个α螺旋线在空间中基本上彼此垂直。该肽可用于检测针对HCV的p21蛋白的抗体，用于检测HCV的全部或部分RNA并制备用于检测，预防或治疗HCV感染的诊断，预防或治疗组合物。

78. 发明申请

WO1997040176A1 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR HEPATITIS C VIRUS (HCV) E2 ANTIGEN 审中-公开
标题翻译： HEPATITIS C病毒（HCV）E2抗原特异性人类单克隆抗体
公开(公告)号：WO1997040176A1
公开(公告)日：1997-10-30
申请号：PCT/EP1997001977
申请日：1997-04-18
申请人： PERSSON, Mats, Axel, Atterdag , ALLANDER, Tobias Erik
IPC分类号： C12N15/62
CPC分类号： C07K16/109 , A61K38/00 , A61K39/42 , C07K2319/00 , A61K2300/00
摘要： The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.
摘要翻译：本发明涉及由丙型肝炎病毒（HCV）特异的免疫球蛋白分子衍生的组合物。更具体地，本发明涉及能够与HCV E2抗原特异性结合的分子。该分子可用于特异性结合测定，亲和纯化方案和用于预防和治疗哺乳动物受试者中HCV感染的药物组合物。因此，本发明涉及对HCV E2抗原特异性的新型人单克隆抗体，这种单克隆抗体的片段，具有与从这些单克隆抗体获得的抗原结合位点，编码那些多肽的结构和功能基本上同源的多肽，以及包含核酸分子。

79. 发明申请

WO1996016673A1 METHOD OF PROMOTING AN IMMUNE RESPONSE WITH A BISPECIFIC ANTIBODY 审中-公开
标题翻译：用双相抗体促进免疫应答的方法
公开(公告)号：WO1996016673A1
公开(公告)日：1996-06-06
申请号：PCT/US1995015476
申请日：1995-11-28
申请人： CHIRON CORPORATION
发明人： CHIRON CORPORATION , RING, David, B.
IPC分类号： A61K39/395
CPC分类号： C07K16/08 , A61K38/00 , A61K2039/505 , C07K16/081 , C07K16/1009 , C07K16/1018 , C07K16/1063 , C07K16/109 , C07K16/14 , C07K16/205 , C07K16/28 , C07K16/283 , C07K16/30 , C07K16/3015 , C07K16/32 , C07K2317/31
摘要： A method of inducing an immune response in a patient is provided. The method involves administration of bispecific molecules capable of recognizing and binding Fc gamma RIII and a second antigen. The second antigen may be a cancer antigen, a viral antigen, a fungal antigen, a parasitic antigen or a toxin. The second antigen may or may not be present in the patient at the time the method of the invention is performed.
摘要翻译：提供了一种诱导患者免疫应答的方法。该方法包括给予能够识别和结合FcγRIII和第二抗原的双特异性分子。第二抗原可以是癌抗原，病毒抗原，真菌抗原，寄生抗原或毒素。在进行本发明的方法时，第二抗原可以或不存在于患者体内。

80. 发明申请

WO1996006164A1 METHOD FOR ISOLATING MUTANT CELLS 审中-公开
标题翻译：分离突变细胞的方法
公开(公告)号：WO1996006164A1
公开(公告)日：1996-02-29
申请号：PCT/US1995010224
申请日：1995-08-10
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , RAY, Bryan, L. , LIN, Edmund, C., C. , CREA, Roberto
IPC分类号： C12N15/00
CPC分类号： C07K14/005 , C07K14/475 , C07K14/505 , C07K16/109 , C07K2319/00 , C12N7/00 , C12N9/6475 , C12N15/00 , C12N15/102 , C12N15/64 , C12N2770/24222 , C12N2795/10343 , C12N2795/10351 , C12Q1/70
摘要： Disclosed is a method for isolating a mutant cell that excretes a desired compound. The method includes culturing a plurality of auxotrophic pretreated starter cells and auxotrophic feeder cells in the presence of a reversibly noninfective, modified lambdoid bacteriophage. If the treated starter cell produces the desired compound, the bacteriophage will be rendered infective and infect the feeder cell. The feeder cell, in turn, will excrete a metabolite required by the starter cell and the starter cell will excrete a metabolite required by the feeder cell, enabling the cells to cross-feed, grow, and produce a colony containing a starter cell which produces the desired compound.
摘要翻译：公开了分离所需化合物的突变细胞的分离方法。该方法包括在可逆的非感染性改良的羔羊噬菌体的存在下培养多种营养缺陷型预处理起始细胞和营养缺陷型饲养细胞。如果处理的起始细胞产生所需化合物，则噬菌体将被感染并感染饲养细胞。饲养细胞又将排出起始细胞所需的代谢物，起始细胞将排出饲养细胞所需的代谢物，使得细胞能够交叉进食，生长并产生含有起始细胞的菌落，其产生产生所需化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式